AbbVie Presented Clinical Data for Crohn's Treatments
The company shared new study results for SKYRIZI and RINVOQ at a recent medical conference in Nashville.
Updated on Oct. 11, 2026 in Asthma
Live Poll
Do you trust that pharmaceutical companies prioritize patient outcomes over their own commercial interests?
AbbVie showcased 22 scientific abstracts detailing the performance of its Crohn's disease treatments at the 2026 American College of Gastroenterology Annual Scientific Meeting. The data included Phase 3 clinical trial results for SKYRIZI and real-world evidence for RINVOQ.
Why it matters
These presentations provide new insights into how these therapies impact endoscopic and clinical outcomes for patients suffering from complex inflammatory bowel disease. The data supports the clinical efficacy of interleukin-23 and JAK inhibitors in managing severe disease burden.
AbbVie presented 22 scientific abstracts at the conference, highlighting Phase 3 trial data that showed higher clinical and endoscopic response rates for SKYRIZI compared to a placebo. The company reports its immunology medicines are currently approved in 175 countries.
The players
AbbVie
A research-based biopharmaceutical company headquartered in North Chicago that develops therapies for complex health conditions including immunology disorders.
American College of Gastroenterology
A professional organization that hosts annual scientific meetings to share clinical advancements and research in the field of digestive health.
The details
The studies, delivered via oral and poster presentations, demonstrate that SKYRIZI, an interleukin-23 inhibitor, provides sustained endoscopic outcomes for patients with complex Crohn's disease. Meanwhile, real-world analyses indicate that RINVOQ, a JAK inhibitor, assists patients with advanced disease in achieving better control.
Timeline
AbbVie submitted an application for SKYRIZI subcutaneous induction on April 27, 2026.
The American College of Gastroenterology 2026 Annual Scientific Meeting took place from October 9-14, 2026.
AbbVie announced the presentation of the clinical data on October 11, 2026.
Health Landscape
This news follows a pattern set by the American College of Gastroenterology Annual Scientific Meeting, which serves as a major venue for pharmaceutical companies to debut Phase 3 trial outcomes. These presentations mark a broader industry shift toward using real-world evidence to complement clinical trial data for complex autoimmune treatments.
These findings expand the body of clinical evidence available to gastroenterologists, potentially helping them tailor treatment plans for patients with complex inflammatory bowel disease. Patients currently prescribed or considering these therapies should consult with their healthcare providers regarding how these specific clinical milestones may affect their individual treatment path.
The takeaway
Advances in biologics and targeted therapies continue to change how clinicians approach chronic autoimmune conditions like Crohn's disease. Patients should remain informed about the latest clinical trial results to better understand the available options for managing their condition long-term.
Further reading
For more information on digestive health therapies, visit the Asthma section.
Live Poll
Do you trust that pharmaceutical companies prioritize patient outcomes over their own commercial interests?
